Avoid common mistakes on your manuscript.
Past
The majority of prognostic models and nomograms for non-muscle-invasive bladder cancer (NMIBC) classify individuals based on their risk of recurrence and progression.1,2,3,4 Exploration of cancer-specific survival (CSS) among NMIBC patients remains limited, owing to the utilization of surrogate endpoints and relatively infrequent occurrence of mortality attributed to bladder cancer (BC) within this cohort. Accurate insights into CSS prognostic determinants for NMIBC necessitate large cohorts within multicenter studies. Presently, comprehensive real-world data concerning survival outcomes and prognostic factors in NMIBC are deficient. We aimed to evaluate real-world CSS in NMIBC and to develop a prognostic nomogram based on identified risk factors.5
Present
Our population-based analysis using the Surveillance, Epidemiology, and End Results database encompassed 98,238 patients with NMIBC who underwent transurethral resection of bladder tumor (TURBT) between 2004 and 2015. Our findings reveal significant disparities in cancer-specific mortality (CSM) across different NMIBC stages. Notably, T1HG and carcinoma in situ (CIS) were associated with the highest CSM rates within the observed follow-up of 124 months [interquartile range (IQR) 81–157], reaching 19.52% and 15.56%, respectively. The study also highlighted the relatively high risk of CSM for rarely diagnosed T1LG and TaHG tumors; the risk being approximately 10%. Our nomogram underlines the crucial relevance of T stage, grade and age in CSM prediction. Sociodemographic factors also influence the CSM, which underscores the disparity in oncological care and should alarm the healthcare providers and policymakers. Estimation of long-term CSM based on identified risk factors might help in patient counseling and aid clinical decision making regarding treatment intensification in ones and de-intensification in others.5
Future
The anticipation of CSS, representing the paramount ultimate endpoint within oncological investigations, holds profound significance within the context of NMIBC. Future research endeavors pertaining to the prediction of progression-free and cancer-specific survival in NMIBC should be directed towards identifying strategies for precisely categorizing the subset of patients with the highest risk, necessitating intensified therapeutic interventions and meticulous surveillance. The development and implementation of innovative therapeutic paradigms remains an unmet need, particularly for individuals with high- and very high-risk NMIBC.4 Potentially synergistic adjuvant regimens after TURBT, accompanied by vigilant cystoscopic monitoring, might offer more effective bladder-sparing approaches, minimizing the need for radical cystectomy. The forthcoming outcomes from ongoing trials involving combinations of Bacillus Calmette–Guérin (BCG) vaccine and promising immunotherapies (e.g., immune checkpoint inhibitors) have the potential to reshape the current therapeutic landscape for high- and very high-risk NMIBC subgroups, thereby amplifying the significance of robust risk stratification strategies.4
References
Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette-Guérin. Eur Urol. 2016;69(1):60–9.
van den Bosch S, Alfred WJ. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. 2011;60(3):493–500.
Sylvester RJ, Rodríguez O, Hernández V, Turturica D, Bauerová L, Bruins HM, et al. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel. Eur Urol. 2021;79(4):480–8.
Ślusarczyk A, Zapała P, Zapała Ł, Piecha T, Radziszewski P. Prediction of BCG responses in non-muscle-invasive bladder cancer in the era of novel immunotherapeutics. Int Urol Nephrol. 2019;51(7):1089–99.
Ślusarczyk A, Zapała P, Zapała Ł, Borkowski T, Radziszewski P. Cancer-specific survival of patients with non-muscle-invasive bladder cancer: a population-based analysis. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-14051-9.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
No conflict of interest to declare.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Ślusarczyk, A. ASO Author Reflections: Cancer-Specific Mortality of Non-Muscle-Invasive Bladder Cancer. Ann Surg Oncol 30, 7910–7911 (2023). https://doi.org/10.1245/s10434-023-14301-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-023-14301-w